(ADMA) ADMA Biologics - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0008991046
IVIG, Immune Globulin, Hepatitis B, Plasma, Immunodeficiency
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 52.0% |
| Value at Risk 5%th | 76.7% |
| Relative Tail Risk | -10.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.18 |
| Alpha | -18.24 |
| CAGR/Max DD | 1.86 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.431 |
| Beta | 1.133 |
| Beta Downside | 1.024 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.92% |
| Mean DD | 14.14% |
| Median DD | 12.51% |
Description: ADMA ADMA Biologics November 07, 2025
ADMA Biologics Inc. (NASDAQ: ADMA) is a U.S.-based biopharma that manufactures and markets specialty plasma-derived products, chiefly intravenous immune globulins (IVIG) such as BIVIGAM and ASCENIV for primary humoral immunodeficiency, and Nabi-HB, a polyclonal antibody for post-exposure prophylaxis against Hepatitis B. The firm also runs its own source-plasma collection network and is developing additional plasma-derived therapeutics targeting Streptococcus pneumoniae infections.
Key operational metrics (as of FY 2023) include ≈ $300 million in net sales, a 12 % year-over-year growth driven largely by ASCENIV’s market uptake, and a plasma collection capacity of roughly 2 million liters per year, placing ADMA in the mid-tier of U.S. plasma collectors. The IVIG market is expanding at ~6 % CAGR, buoyed by an aging population and increasing diagnoses of immune deficiencies, while reimbursement pressure from Medicare’s “bundled” payment reforms remains a sector-wide risk factor.
For a deeper dive into ADMA’s valuation metrics and peer comparison, consider exploring the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (209.4m TTM) > 0 and > 6% of Revenue (6% = 29.3m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -13.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.85% (prev 71.39%; Δ -0.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 65.0m <= Net Income 209.4m (YES >=105%, WARN >=100%) |
| Net Debt (21.7m) to EBITDA (172.1m) ratio: 0.13 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (244.7m) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 54.71% (prev 48.93%; Δ 5.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 101.9% (prev 98.00%; Δ 3.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.63 (EBITDA TTM 172.1m / Interest Expense TTM 8.36m) >= 6 (WARN >= 3) |
Altman Z'' 3.47
| (A) 0.61 = (Total Current Assets 402.7m - Total Current Liabilities 56.5m) / Total Assets 568.7m |
| (B) -0.37 = Retained Earnings (Balance) -211.0m / Total Assets 568.7m |
| (C) 0.34 = EBIT TTM 164.1m / Avg Total Assets 479.7m |
| (D) -1.53 = Book Value of Equity -211.0m / Total Liabilities 137.5m |
| Total Rating: 3.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.99
| 1. Piotroski 5.50pt |
| 2. FCF Yield 0.99% |
| 3. FCF Margin 8.34% |
| 4. Debt/Equity 0.19 |
| 5. Debt/Ebitda 0.13 |
| 6. ROIC - WACC (= 17.30)% |
| 7. RoE 53.98% |
| 8. Rev. Trend 98.04% |
| 9. EPS Trend 91.89% |
What is the price of ADMA shares?
As of December 04, 2025, the stock is trading at USD 19.72 with a total of 2,634,928 shares traded.
Over the past week, the price has changed by +3.03%, over one month by +28.30%, over three months by +16.69% and over the past year by -1.00%.
Over the past week, the price has changed by +3.03%, over one month by +28.30%, over three months by +16.69% and over the past year by -1.00%.
Is ADMA a buy, sell or hold?
ADMA Biologics has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy ADMA.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADMA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.3 | 38.2% |
| Analysts Target Price | 27.3 | 38.2% |
| ValueRay Target Price | 31.3 | 58.6% |
ADMA Fundamental Data Overview November 25, 2025
Market Cap USD = 4.10b (4.10b USD * 1.0 USD.USD)
P/E Trailing = 19.9767
P/E Forward = 28.9855
P/S = 8.3914
P/B = 9.4827
Beta = 0.448
Revenue TTM = 488.6m USD
EBIT TTM = 164.1m USD
EBITDA TTM = 172.1m USD
Long Term Debt = 70.1m USD (from longTermDebt, last quarter)
Short Term Debt = 3.64m USD (from shortTermDebt, last quarter)
Debt = 83.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.12b USD (4.10b + Debt 83.1m - CCE 61.4m)
Interest Coverage Ratio = 19.63 (Ebit TTM 164.1m / Interest Expense TTM 8.36m)
FCF Yield = 0.99% (FCF TTM 40.7m / Enterprise Value 4.12b)
FCF Margin = 8.34% (FCF TTM 40.7m / Revenue TTM 488.6m)
Net Margin = 42.87% (Net Income TTM 209.4m / Revenue TTM 488.6m)
Gross Margin = 54.71% ((Revenue TTM 488.6m - Cost of Revenue TTM 221.3m) / Revenue TTM)
Gross Margin QoQ = 56.34% (prev 55.11%)
Tobins Q-Ratio = 7.25 (Enterprise Value 4.12b / Total Assets 568.7m)
Interest Expense / Debt = 2.02% (Interest Expense 1.68m / Debt 83.1m)
Taxrate = 23.33% (11.1m / 47.5m)
NOPAT = 125.8m (EBIT 164.1m * (1 - 23.33%))
Current Ratio = 7.13 (Total Current Assets 402.7m / Total Current Liabilities 56.5m)
Debt / Equity = 0.19 (Debt 83.1m / totalStockholderEquity, last quarter 431.2m)
Debt / EBITDA = 0.13 (Net Debt 21.7m / EBITDA 172.1m)
Debt / FCF = 0.53 (Net Debt 21.7m / FCF TTM 40.7m)
Total Stockholder Equity = 388.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 36.83% (Net Income 209.4m / Total Assets 568.7m)
RoE = 53.98% (Net Income TTM 209.4m / Total Stockholder Equity 388.0m)
RoCE = 35.83% (EBIT 164.1m / Capital Employed (Equity 388.0m + L.T.Debt 70.1m))
RoIC = 27.32% (NOPAT 125.8m / Invested Capital 460.7m)
WACC = 10.02% (E(4.10b)/V(4.18b) * Re(10.19%) + D(83.1m)/V(4.18b) * Rd(2.02%) * (1-Tc(0.23)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.05%
[DCF Debug] Terminal Value 61.43% ; FCFE base≈56.1m ; Y1≈36.8m ; Y5≈16.8m
Fair Price DCF = 1.02 (DCF Value 241.8m / Shares Outstanding 238.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 91.89 | EPS CAGR: 103.9% | SUE: 0.12 | # QB: 0
Revenue Correlation: 98.04 | Revenue CAGR: 54.31% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.96 | Chg30d=+0.030 | Revisions Net=+0 | Growth EPS=+61.3% | Growth Revenue=+24.3%
P/E Trailing = 19.9767
P/E Forward = 28.9855
P/S = 8.3914
P/B = 9.4827
Beta = 0.448
Revenue TTM = 488.6m USD
EBIT TTM = 164.1m USD
EBITDA TTM = 172.1m USD
Long Term Debt = 70.1m USD (from longTermDebt, last quarter)
Short Term Debt = 3.64m USD (from shortTermDebt, last quarter)
Debt = 83.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.12b USD (4.10b + Debt 83.1m - CCE 61.4m)
Interest Coverage Ratio = 19.63 (Ebit TTM 164.1m / Interest Expense TTM 8.36m)
FCF Yield = 0.99% (FCF TTM 40.7m / Enterprise Value 4.12b)
FCF Margin = 8.34% (FCF TTM 40.7m / Revenue TTM 488.6m)
Net Margin = 42.87% (Net Income TTM 209.4m / Revenue TTM 488.6m)
Gross Margin = 54.71% ((Revenue TTM 488.6m - Cost of Revenue TTM 221.3m) / Revenue TTM)
Gross Margin QoQ = 56.34% (prev 55.11%)
Tobins Q-Ratio = 7.25 (Enterprise Value 4.12b / Total Assets 568.7m)
Interest Expense / Debt = 2.02% (Interest Expense 1.68m / Debt 83.1m)
Taxrate = 23.33% (11.1m / 47.5m)
NOPAT = 125.8m (EBIT 164.1m * (1 - 23.33%))
Current Ratio = 7.13 (Total Current Assets 402.7m / Total Current Liabilities 56.5m)
Debt / Equity = 0.19 (Debt 83.1m / totalStockholderEquity, last quarter 431.2m)
Debt / EBITDA = 0.13 (Net Debt 21.7m / EBITDA 172.1m)
Debt / FCF = 0.53 (Net Debt 21.7m / FCF TTM 40.7m)
Total Stockholder Equity = 388.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 36.83% (Net Income 209.4m / Total Assets 568.7m)
RoE = 53.98% (Net Income TTM 209.4m / Total Stockholder Equity 388.0m)
RoCE = 35.83% (EBIT 164.1m / Capital Employed (Equity 388.0m + L.T.Debt 70.1m))
RoIC = 27.32% (NOPAT 125.8m / Invested Capital 460.7m)
WACC = 10.02% (E(4.10b)/V(4.18b) * Re(10.19%) + D(83.1m)/V(4.18b) * Rd(2.02%) * (1-Tc(0.23)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.05%
[DCF Debug] Terminal Value 61.43% ; FCFE base≈56.1m ; Y1≈36.8m ; Y5≈16.8m
Fair Price DCF = 1.02 (DCF Value 241.8m / Shares Outstanding 238.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 91.89 | EPS CAGR: 103.9% | SUE: 0.12 | # QB: 0
Revenue Correlation: 98.04 | Revenue CAGR: 54.31% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.96 | Chg30d=+0.030 | Revisions Net=+0 | Growth EPS=+61.3% | Growth Revenue=+24.3%
Additional Sources for ADMA Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle